CO102 Physician Reported Treatment Attributes Considered in First-Line and Perceptions Around Bruton Tyrosine Kinase Inhibitor (BTKi) Treatments in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) in the US
Abstract
Authors
C. Jensen Z. Ding T. Greenwood C. Kluth I. Sanderson N. Milloy H. Mavani W. Khan Z.P. Qureshi